Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: J Immunother. 2013 Oct;36(8):10.1097/CJI.0b013e3182a80213. doi: 10.1097/CJI.0b013e3182a80213

Figure 2. ARI-4175 modulates the myeloid cell populations in secondary lymphoid tissues.

Figure 2

Figure 2

Mice were injected with MB49 and treated with ARI-4175 as described in Figure 1. (A) On day 9 complete blood counts showed a significant increase in platelet count at both the 5 μg and 200 μg ARI-4175 doses. (B) Splenocytes from tumor-challenged mice analyzed on day 11 of ARI-4715 treatment for expression of CD11c and CD11b showed an increase in CD11b+ cells at the 200 μg dose. (C-E) Changes in the frequency and absolute number of CD11b+CD11c+ mDCs (C), CD11b+CD11c- myeloid cells (D), and CD11b-CD11c+ pDCs (E) on day 11 in spleen and TDLN of ARI-4175 treated MB49-challenged mice. (F) Further characterization of CD11b+CD11c- myeloid cells in the spleen and TDLN demonstrated an increase in proportion of Ly6CloLy6Ghi granulocytic myeloid cells and a decrease in proportion of Ly6ChiLy6Glo monocytic cells in TDLN with ARI-4175 treatment. A modest decrease in proportion of Ly6CloLy6Ghi granulocytic myeloid occurred in the spleen. * p<0.05, **p<0.01. n=6 mice per group. Data representative of 3 independent experiments.